Why Is Cholesterol Present in the Lung? {#S1}
=======================================

As recently reviewed by [@B231], 2.32 billion years ago, the atmospheric oxygen raised ([@B22]) leading to many changes in life. One of these changes may have been the appearance of sterols, around 2.7 billion years ago ([@B29]; [@B59]) after the GOE (Great Oxygen Event) as suggested by fossil evidences. However, which is the connection between oxygen and sterols? It has been proposed that sterols emerged as an evolutionary strategy to reduce oxygen diffusion through cellular membranes, probably in a world where organisms were not ready to respond to oxidative stress yet. Interestingly, sterol biosynthesis is highly dependent on oxygen ([@B48]).

How can sterols, such as cholesterol, regulate oxygen diffusion through biological membranes? The molecular mechanism by which cholesterol can influence small solute permeation and diffusion through lipid membranes is not well understood. However, it has been proposed that the interactions between cholesterol and the acyl carbon chains in phospholipids (stabilized by Van der Waals' forces) ([@B220]) create tightly packed arrangements that limits small molecule diffusion ([@B230]). By decreasing trans-gauche rotation of the phospholipid acyl chains, membrane rigidity increases ([@B36]; [@B138]) leading to less free volume and free pockets which may accommodate oxygen, therefore reducing its flux (its partition and diffusion) through membranes ([@B231]).

Mammals developed sophisticated organs to optimize the uptake of oxygen during the life essential breathing cycle. From conducting airways to the second biggest surface exposed to the environment, the alveolar human surface ([@B148]). In addition, the first membrane that oxygen encounters in the mammalian lungs is a complex mixture of lipids (mainly phosphatidylcholines (PC), such as dipalmitoylphosphatidylcholine (DPPC), up to a 90%) and proteins (10%) with a 5--10% of cholesterol (14--20% mol) ([@B232]; [@B24]), called lung surfactant (surface active agent). Interestingly two surfaces in the human body present with abnormally higher cholesterol molar ratio, and both of them are in contact with the environment tightly regulating the uptake of oxygen. On the one hand, as previously explained, lung surfactant presents around a 14--20% mol cholesterol in its composition. On the other hand the eye lens surface contains up to 35% mol of cholesterol ([@B168]; [@B127]), compared to a normal cell plasma membrane with a 0.5 phospholipid to cholesterol molar ratio ([@B206]; [@B221]). Although the main function of lung surfactant has not been related to oxygen flux control, it has been described to accelerate oxygen diffusion through a water layer ([@B150]), reflecting the importance of lung surfactant as potential oxygen flux regulator. The main function of lung surfactant is to reduce surface tension in order to prevent alveolar collapse during expiration and therefore stabilizing open alveoli allowing oxygen to diffuse through the lung tissue to the blood ([@B100]; [@B18]; [@B99]). Alveolar parenchyma is thin enough to allow oxygen diffusion and is composed of a minimum of three components: (1) alveolar epithelium, where alveolar epithelial type I cells (AE1C) cover 60% of the surface with a small cytoplasm but in a long and thin disposition, whereas alveolar type II cells (AE2C) are in charge of synthesizing, secreting and regulating surfactant composition; (2) both cells sit on a very thin basal membrane; (3) to which a thin endothelium is attached on the opposite side, creating a thin but extensive air-blood barrier. The last step oxygen encounters in its way to the rest of the organs is the erythrocyte membrane. Red blood cells present a rather high cholesterol content, which comprises a 1:1 phospholipid to cholesterol ratio ([@B231]). In addition, it has been described that oxygen diffusion through red blood cell membranes is decreased in the presence of increased cholesterol content ([@B30]). And therefore, reduction of cholesterol content in those membranes (such as after the use of Simvastatin for 12 weeks) improves oxygen diffusion rate ([@B135]).

In the long way of oxygen through the human body this review focuses on the first barrier, lung surfactant and how its components may impact the normal function of the lung. There is a particular interest in the relevance of the role of cholesterol, and more specifically, in the long described potential relation between surfactant protein C (SP-C) and cholesterol content in lung surfactant. Here, we described the state of the art at the molecular level, contrasting with data from animal models and human patients, where lung mechanics and alveolar dynamics is affected during SP-C deficiency related disease.

Is There a Relationship Between SP-C and Cholesterol? {#S2}
=====================================================

Known Functions of SP-C {#S2.SS1}
-----------------------

SP-C is the smallest (4.2 kDa) and most hydrophobic protein in lung surfactant. It accounts for ∼1% of lung surfactant mass, becoming the most abundant protein in molar terms. SP-C appeared relatively late in evolution and its sequence has remained highly conserved among species ([@B164]). The lack of any known homologous protein and its confined expression ([@B105]), makes it a specific marker associated with the differentiation of lung tissue, and particularly of AE2C. SP-C exists as a 35 amino acid transmembrane protein expressed as a larger precursor (21 kDa) in AE2C cells. Structurally, it adopts a metastable α-helical structure, although its high proportion of branched residues makes it prone to adopt β-sheet structures and fibrillogenic amyloid-like aggregates ([@B92]; [@B93]; [@B41]), a common feature in several interstitial lung diseases such as pulmonary fibrosis. SP-C greatly alters lipid packing in membranes influencing lipid motion and lateral distribution ([@B140]; [@B49]). As described before, this may also influence the availability of free volume and free pockets, which may accommodate oxygen. However, a direct study of SP-C content and oxygen diffusion through surfactant membranes has not been assessed so far. SP-C also increases membrane permeability ([@B162]; [@B157], [@B156]) and promotes interfacial lipid adsorption and lipid transfer among different lipid structures ([@B47]; [@B163]; [@B218]). SP-C is responsible for the reversible formation of multilayered stacks connected to the interfacial monolayer ([@B6]; [@B218]). Doing so, it allows the capture of surfactant material presumably squeezed out during exhalation (area compression) and surfactant re-spreading upon inhalation (area expansion). In this process, protein palmitoylation seems to be relevant to sustain protein association to the highly compressed interfacial films reached during exhalation ([@B161]; [@B122]).

SP-C-associated functions overlap in many cases with surfactant protein B (SP-B) activity, at least when assayed in different *in vitro* models. This includes facilitating lipid adsorption ([@B47]; [@B163]; [@B218]) into the air-liquid interface or generating 3D structures that serve as a surfactant reservoir ([@B6]; [@B218]), which store newly secreted surfactant complexes and surfactant molecules squeezed out from the interface upon compression. In this context, SP-C could be figured as a supporting molecule for SP-B function rather than an element competent by itself to assist specific features of the complex and dynamic surfactant functionality. Nevertheless, considering the extensive processing of SP-C to its mature form, its extremely conserved sequence and tissue-specific localization, and the difficulties that a cell must overcome to produce and store such a hydrophobic molecule, it is unlikely that this peptide appeared evolutionarily just as an alternative strategy to assist SP-B activities.

SP-C and Cholesterol Relationships in the Lung Surfactant Context {#S2.SS2}
-----------------------------------------------------------------

Surfactant cholesterol represents a paradox regarding its origin ([@B152]; [@B121]). Some works have suggested that it is supplied by the low and high-density lipoproteins present in blood circulation ([@B149]). However, other studies have failed to prove that circulating cholesterol ends up forming part of surfactant complexes ([@B152]; [@B136]), suggesting that other possible sources must be taken into account. It is remarkable that cholesterol levels in surfactant are tightly regulated to ensure a proper breathing function, and they are able to increase and decrease extremely fast in response to changes in temperature or breathing rate ([@B51]; [@B153]). This seems to imply that a cholesterol reservoir might exist in order to provide cholesterol at fast rates when an increase is required. A specific cell type, the lipofibroblast, has been suggested as a reservoir of cholesterol ([@B25]; [@B202]), although further validation is required to confirm its presence through different organisms and whether it constitutes a surfactant cholesterol storage. AE2C cells are able of producing cholesterol in peroxisomes ([@B17]), but alveolar macrophages (AMs) also exhibit enzymes involved in cholesterol synthesis ([@B13]). Elucidating how cholesterol levels are regulated in the context of surfactant physiology is key to understand responses associated with several respiratory pathologies, especially those characterized by the incorporation in surfactant of abnormal cholesterol amounts such as the acute respiratory distress syndrome (ARDS) ([@B213]) or pulmonary alveolar proteinosis (PAP).

The presence of cholesterol induces a marked segregation of fluid phases in surfactant ([@B23]; [@B98]), and variations in cholesterol levels are known to adapt surfactant structures extremely fast to defined physiological situations ([@B51]; [@B152]). This evidence highlights cholesterol as a structural modulator of surfactant membranes and films. Besides, mechanisms involved in cholesterol sensing and mobilization may be evolutionary conserved to regulate cholesterol levels in surfactant. On the other hand, some studies suggest that SP-C might be involved in cholesterol regulation ([@B72], [@B73]; [@B20]; [@B173], [@B174]), which could also be linked to the role of SP-C in lung homeostasis. Therefore, the role of SP-C in cholesterol mobilization and dynamics could be tracked back to a combined effect of protein- and cholesterol-induced alterations on membrane structure. In fact, an increase in cholesterol motion was described upon incorporation of SP-C into lung surfactant-derived vesicles ([@B173]), an effect potentially associated to SP-C-promoted membrane-fragmenting effect ([@B157], [@B156]; [@B173]). Besides, SP-C and cholesterol have been also related to modulating membrane architecture responding in a coordinate manner to temperature changes ([@B174]), suggesting that SP-C is involved in cholesterol mobilization by altering membrane structure ([@B173]). In addition, taking into account that SP-C supplementation restores the functionality of cholesterol-containing films in a dynamic context ([@B73]; [@B20]), we could hypothesize that SP-C could be related to the compositional refinement of lung surfactant films from less surface-active molecules, involving cholesterol and other unsaturated phospholipids. Interestingly, observations made by [@B114] could support this hypothesis. The incorporation of increasing amounts of cholesterol in a surfactant clinical preparation resulted in structurally and functionally different interfacial films ([@B77]; [@B114]). Compression-expansion isotherms allowed the determination of lipid loss from the interfacial film upon compression, which were considerably low for physiological cholesterol amounts, permitting the re-establishment of a functional interfacial film ([@B77]; [@B114]). Shifting that to SP-C function, lipid loss occurring for physiological cholesterol levels could be associated with a SP-C-dependent cholesterol refinement, in which SP-C-induced lipid reorganizations could be involved. However, lipid loss increased substantially for cholesterol concentrations beyond physiological levels, showing a markedly different film structure and impaired functionality ([@B77]; [@B114]). For these supra-physiological cholesterol levels, the SP-C amount present in a clinical surfactant preparation like the one tested in this study (∼1 wt%), could be likely insufficient to overcome cholesterol impairing effects and the irreversible film collapse. Supplementation of these films with different SP-C amounts would provide valuable information to confirm SP-C effects on cholesterol mobilization.

SP-C/cholesterol relationships might be involved in surfactant refinement with a homeostatic purpose in the lung. Both, cholesterol-loaded vesicles, as well as their combination with SP-C, led to a higher lipid engulfment by AMs ([@B178]). Increased cholesterol content, however, seemed to increase lipid uptake by AMs regardless of the presence of SP-C. Vesicle size and membrane fluidity can affect lipid uptake by AMs ([@B95]), and thus, the combined effect of cholesterol and SP-C on membrane structure and fluidity ([@B173], [@B174]) is a factor that must be taken into account. The study of the transcriptional response of MH-S cells to lipid administration revealed that genes associated to lipid metabolism and cholesterol transport were altered upon lipid uptake. Changes in gene expression appear to depend on lipid composition, including the presence or absence of SP-C and/or cholesterol. However, specific effects of cholesterol and SP-C require a thorough and extensive analysis, which also warrant a deeper exploration of the poorly studied pathways for cholesterol synthesis, degradation and mobilization in AMs.

SP-C could then be considered as a pivotal molecule linking cholesterol and lipid homeostasis, lung immunity, lung surfactant biophysical activity and potentially oxygen diffusion regulation, which would explain its particular features, lung tissue specific localization and sequence conservation along evolution. Several questions remain to be answered, including how SP-C effects are coordinated with SP-B function to modulate surfactant activity; which are the molecular mechanisms and SP-C structural determinants involved in membrane reorganizations and how cholesterol levels in surfactant are sensed and regulated regarding SP-C function by both AE2C and AMs. Future research assessing these questions would constitute an essential piece to understand the molecular mechanisms ruling lung surfactant behavior and its implication in respiratory pathologies, generating valuable information useful to improve the current clinical preparations applied for surfactant replacement therapy.

SP-C, Cholesterol and Alveolar Micromechanics {#S3}
=============================================

SP-C Deficiency Predisposes to Alveolar Instability {#S3.SS1}
---------------------------------------------------

According to LaPlace law, the intra-alveolar pressure of and idealized isotropic alveolus is inversely proportional to its radius. Therefore, at end-expiration, the breathing stage in which the intra-alveolar volume reaches its minimum (ignoring rare occurring phenomena like Pendelluft; [@B195]), the intra-alveolar pressure reaches its maximum. Under physiologic conditions, end-expiratory pressure is homogenously distributed among the alveoli and surface tension is low enough preventing alveolar collapse. To maintain alveolar pressure throughout the lung constant, surface tension also changes accordingly to alveolar radius ([Figure 1](#F1){ref-type="fig"}).

![Schematic model of Young-La Place law in the acinar airways. The inner pressure of an idealized spherical alveolus is defined by the Young-La Place law as ΔP = 2γ/r. Therefore, alveoli with small radius (alveolus 1) comprise higher internal pressures in relation to alveoli with larger radius (alveolus 2). Accordingly, alveolus 1 would tend to collapse toward alveolus 2 under the absence of a functional surfactant film, what permits alveolar size heterogeneity **(left panel)**. However, in the presence of surfactant, surface tension is reduced as intermolecular forces are homogenously generated between water-water- and water-air phase, avoiding bending of the air-liquid interface and avoiding alveolar collapse **(right panel)**. LS, lung surfactant.](fphys-11-00386-g001){#F1}

However, during expiration the surfactant film collapses and thus, end-expiratory surface tension may drastically increase and lead to higher intra-alveolar pressures as well as a rather heterogeneous inter-alveolar pressure distribution. As the intra-alveolar pressure is *per se* higher in small-radius alveoli (relative to its larger neighbors) by its anatomy, this may increase the likelihood of alveolar collapse. Hence, it has been described that the result of surfactant dysfunction in a murine model of AE2C apoptosis is ductal airspace over distension together with alveolar collapse ([@B141]). On the one hand, this may explain the increased vulnerability of small subpleural alveoli to surfactant dysfunction. On the other hand, points toward an essential role of alveolar collapse in fibrotic remodeling, as collapsing alveoli was proposed to be the initiating hotspot in pulmonary fibrogenesis ([@B126]; [@B100]; [@B160]).

Alveolar Collapse -- The Springboard for Lung Mechanic Impairment {#S3.SS2}
-----------------------------------------------------------------

The central role of alveolar collapse in the development of diseases such as lung fibrosis is not a novel finding and was already stated by [@B142]. Moreover, alveolar collapse induced by surfactant dysfunction has also been well described in the field of ARDS and acute lung injury (ALI) ([@B18]; [@B144]). Although the increase in surface tension and alveolar instability is much more pronounced in ARDS ([@B188]; [@B8]) than under SP-C deficiency, leading to a rather acute than chronic respiratory pathology, ARDS as well as rather chronic lung fibrosis may be associated with a similar underlying disease mechanism. This is highlighted by the fact that alveolar collapse, respiratory distress and concomitant ventilation in-homogeneities haven been demonstrated to be present in patients from both diseases ([@B201]; [@B4]; [@B8]; [@B160]). Moreover, pulmonary fibrosis is also seen in later disease stage of ARDS patients, resembling an aberrant pulmonary repair mechanism in response to lung injury ([@B81]), which has also been stated to be the major mechanism of disease in idiopathic pulmonary fibrosis (IPF) patients ([@B190]).

Atelectrauma and volutrauma are two mechanism contributing to tissue injury in ARDS ([Figure 2](#F2){ref-type="fig"}). In the injured lung, repetitive alveolar collapse (atelectrauma) is caused by increased surface tension (induced by various agents). During the inspiration phase, the transpulmonary pressure gradient increases until the alveolar pressure of the closed (de-recruited) alveolus is exceeded and is re-opened (recruited). If the maximal generated transpulmonary pressure fails to exceed the intra-alveolar pressure, the alveolus remains collapsed and its alveolar walls stay adjacent to each other. This model is supported by findings of Bachofen and Schürch, who described alveolar wall stretching and ductal airspace over distension on electron microscopic images resulting from surfactant inactivation-induced alveolar collapse ([@B10]). Considering the mechanism of atelectrauma, the alveolar lining fluid should not be neglected. Weibel and Gil first described the alveolar lining lavage as an interfacial film and sub-interfacial liquid reservoir defined as the hypophase ([@B219]). As the alveolus deflates during expiration, its defining septa start to fold. The folding septal branches are continuously filled with this alveolar lining fluid during expiration ([@B177]). Under increased surface tensions the alveolus is further de-recruited leading to more pronounced septal folding and enhanced inter-septal liquid accumulation. During inspiration, an increasing transpulmonary pressure is generated by the respiratory muscles ([@B133]; [@B63]). As soon as this pressure exceeds the end-expiratory intra-alveolar pressure, a bubble of air is forced through the lining fluid between the septal folds in order increase alveolar volume by forcing septal de-folding. During this process mechanical axial shear stresses are generated with the air-bubble moving toward the lining fluid, leading to injurious deformation of AEC2 ([@B26]). Of note, the cell damaging force vectors strongly increase with rising surface tension at the interface of the lining fluid, as the speed of the bubble is highly reduced ([@B37]; [@B64]). Meanwhile, AEC2 injury impairs the epithelial functional integrity resulting in accumulation of alveolar edema and reduced rates of surfactant production. Thus, starting a vicious cycle leading to continuously increasing surface tension and epithelial injury, resulting in AEC2 hyperplasia and fibrosis ([@B56]; [@B141]; [@B186]) ([Figure 2](#F2){ref-type="fig"}).

![Surfactant dysfunction related atelectrauma and volutrauma. According to the La Place law ([Figure 1](#F1){ref-type="fig"}) surfactant dysfunction predisposes alveoli for collapse. Alveolar micro-atelectasis causes septal distortion of neighboring alveoli due septal, interalveolar architectural dependence. Thereby the collapsed alveolus acts as a stress concentrator leading to injurious mechanical deformation of neighboring epithelial cells (blue-red color transition) during the breathing cycle (volutrauma). Meanwhile, every time a bubble of air is forced into the atelectatic, lining-fluid filled alveolus during inspiration, as a result of increasing transpulmonary pressures, extremely damaging shear stresses are generated on the epithelium (atelectrauma), further potentiating damage of the alveolar epithelium ([@B18]; [@B177]).](fphys-11-00386-g002){#F2}

In the healthy parenchymal lung architecture, tissue stress and stretch occurring during breathing are homogenously distributed. However, if certain alveolar regions become atelectatic, homogenous ventilation is significantly impaired. Alveolar collapse leads to microscale air redistribution, resulting in an inhomogeneous alveolar size distribution before inspiration ([@B133]). According to alveolar anatomy, single septal walls usually build the parenchymal border of two neighboring alveoli, also known as alveolar interdependence ([@B99]). If one of these alveoli collapses, septal distortion of the adjacent alveoli leads to rising mechanical stresses ([@B133]). Hence, atelectatic alveoli act as stress concentrators and amplify the applied stresses and strains of their neighbors ([@B18]). During inspiration and increasing lung volumes, this phenomenon becomes even more relevant: transpulmonary pressures generated during inspiration will initially rather lead to over inflation of the already enlarged, distorted alveoli than reopening the atelectatic ones. This causes further alveolar over distension during inspiration. During over distension, an alveolus is first fully de-folded before its wall is stretched. Therefore, the effective septal deformation (= strain) strongly depends on the inspired/applied tidal volume and the alveolar "baseline" shape during resting expiratory position. Usually mechanical stretch primarily occurs under rather high pressures reaching over the upper inflection point of the pulmonary pressure-volume curve ([@B99]). However, when inflating a healthy lung beyond total lung capacity (TLC) of 80% the extracellular matrix components of the alveolar septa, collagen and elastin, become the major stress bearing components, thus mechanical forces start acting on the septal interstitium ([@B11]; [@B99]). Moreover, single vulnerable alveoli in proximity to stress concentrators, may already get stretched at physiologic low tidal volumes ([@B133]). In line with this, [@B102] found pulmonary injury in surfactant depleted pig lungs already at physiologic tidal volumes (6 ml/kg bodyweight), while pigs with maintained surfactant function, required a drastically higher degree of volutrauma to induce relevant lung injury (30 ml/kg bodyweight). In the ARDS lung atelectrauma and volutrauma act synergistically to induce vascular leakage. [@B189], [@B188] elegantly demonstrated that initial epithelial injury by atelectrauma predisposes septal walls for volutrauma, leading to significant leakage of the gas-blood barrier. Ventilated mice lungs only developed high concentrations of BALF protein levels, an indicator for gas-blood barrier integrity, when ventilated at PEEP (positive end-expiratory pressure) of 0cmH2O (atelectrauma) in combination with mid or high tidal volumes (volutrauma) (see [Figure 2](#F2){ref-type="fig"}). Meanwhile, neither atelectrauma nor volutrauma alone were sufficient to induce pulmonary edema ([@B188]). As alveolar epithelial cell (AEC) damage has been demonstrated to precede edema formation ([@B177]), the absence of alveolar edema in the SP-C deficient lung ([@B178]), does not rule out the relevance of this protein in preventing alveolar collapse and alveolar over distension, which commonly lead to microscale tissue injuries. Interestingly, hyperplastic AEC2 are present in a global SP-C knock out (KO) mouse model, which may resemble a reaction to chronic mechanical stress ([@B66]; [@B178]). Moreover, surfactant dysfunction in a chronic murine model of AEC injury impressively demonstrated the long-term effects of chronic airway instability to cause microarchitectural air re-distribution resulting in an emphysema-like phenotype, which is characterized by collapsed alveoli and enlarged alveolar ducts ([@B141]). Furthermore, repetitive insults during dynamic strain have been related to more harmful properties on AEC integrity than constant high static strains ([@B145]). This may further emphasize the relevance of airway instabilities, in the absence of volutrauma, in a rather chronic setting, as occurs in IPF patients, where recruitment/de-recruitment cycles take place over a long period of time. In line with this, "velcro-crackles" have been often described to precede computer tomographic changes in IPF lungs. Indeed, they are considered the auditory correlate of damaging energy-rich alveolar re-openings during inspiration, supporting the clinical relevance of impaired alveolar micromechanics in fibrosing lung diseases ([@B215]).

At the lung mechanical macroscale level, alveolar collapse and surfactant dysfunction exhibit notable influence on the lung's viscoelastic properties. Collapsed airways require high amounts of energy to be reopened, while dysfunctional surfactant increases the hysteresis effect in inflating lungs by rising surface tension. This effect results in parenchymal stiffening, increasing levels of pulmonary tissue elastance ([@B189]; [@B27]). During inspiration, the energy applied is rather dissipated creating injurious axial force vectors on the airway epithelium than being stored in the septal elastic fiber network. Therefore, pulmonary tissue damping rises accordingly. In line with this, data from our group demonstrated a significant increase in tissue damping and tissue elastance in 10 weeks old SP-C deficient mice in contrast to age-matched control mice, supporting the concept of alveolar collapse as an initial trigger ([@B178]). During aging, redistribution of air as well as ECM (Extracellular Matrix) remodeling may alter lung mechanics consistent with findings of [@B65], [@B66]. Indeed, this work emphasized aberrant tissue hysteresivity (the quotient of energy dissipative forces and lung elastance) at low PEEP, a condition where alveoli are prone to collapse. At those low lung volumes, surfactant becomes the major defining factor of pulmonary breathing mechanics ([@B11]). Moreover, pressure-volume loops demonstrated an increased pulmonary hysteresis, which also reflects increased energy dissipation during inflation of the lung. [@B63] already suggested this energy to be potentially harmful for the pulmonary tissue, as it is not reused for elastic recoil properties. Persistent septal micro injury may be, in turn, a relevant factor for altered AEC2 biology, aberrant wound repair, pulmonary inflammation and interstitial fibrotic remodeling. Phenomena described in a number of children suffering interstitial lung disease (chILD), who showed reduced or absent levels of mature SP-C ([@B43]), as described in the next sections.

Establishing Injurious Mechanical Stress as a Driving Factor for Fibrogenesis {#S3.SS3}
-----------------------------------------------------------------------------

Under healthy conditions and homogenously distributed lung stress, plasma membrane injury of AEC is normally seen. Indeed, AEC are highly capable of Ca^2+^ and lysosome dependent repair mechanisms as well as membrane folds for preventing cellular damage ([@B43]). However, lysosomal stress as seen in Hermansky-Pudlack Syndrome (HPS) patients may impair cellular repair, favoring profibrotic wound repair and the development of unusual interstitial pneumonia (UIP) ([@B154]; [@B103]). Moreover, if high parenchymal stress leads to plasma membrane defects of more than 1 μm, aberrant AEC wound repair cascades are induced ([@B43]). Very high strains induced by pressure above 40cmH~2~O have been shown to be sufficient to cause membrane blebbing and cellular apoptosis ([@B52]).

Typically, AEC injury response includes signaling of several mechano-transduction pathways including the transforming growth factor β1 (TGF-β1), Wnt β-catenin, sonic hedgehog (Shh), and the Notch-midkine signaling pathways as well as induction of endoplasmic reticulum (ER) stress. Interestingly, all these pathways have been interlinked with the induction of profibrotic genes, epithelial-to-mesenchymal transition (EMT) or increased ECM deposition. Moreover, ER stress is known to compromise the secretory capacity of AEC2, impairing surfactant metabolism, which initiates a vicious cycle of alveolar instability and stress-mediated AEC injury ([@B43]). In a murine model of chloride acid (HCl) induced surfactant depletion, impaired lung mechanics was characterized by increased tissue elastance. This was followed by an increased expression of various mesenchymal markers, such as α-smooth muscle actin (α-SMA) and vimentin in AEC2, whereas the expression of epithelial cell markers, including pro-SP-B, were reduced ([@B32]; [@B130]). Consequently, EMT may be a potent second hit even further compromising: (1) surfactant function and; (2) the regenerative capacitiy of the pulmonary epithelium further directing the damage response toward fibrosis. TGF-β1 is expressed by both AECs as well as resident inflammatory cells like AM ([@B179]). In addition, a large pool of latent-inactive TGF-β1 is located as a complex with latency associated peptide 1 (LAP-1) and latency TGF-β1 binding protein-1 (LTP-1) in the ECM ([@B87]; [@B179]). In the healthy lung, during inspiration, ECM fiber stretching is not sufficient to release active TGF-β1 from its inhibitory binding complex. However, as soon as pulmonary tissue stiffening occurs, interstitial fibroblasts are primed toward myofibroblast differentiation by expressing contractile actin-myosin elements ([@B229]). This drastically increases the likelihood of TGF-β1 release upon parenchymal strain, as myofibroblast are able to bind LAP-1 via αV-integrins ([@B86]; [@B87]). Interestingly, increased epithelial injury resulted in increased expression of epithelial αVß6-integrins, further potentiating the release of TGF-β1 by mechano-transduction ([@B185]). In line with this, [@B60] showed increased expression and release of TGF- β1 in fibrotic IPF lungs, which are characterized by parenchymal stiffening. Importantly the pressures generated by Froese and his team rather reflected gradients comparable to pressure induced by spontaneous breathing than high unphysiological gradients, emphasizing the role of spontaneous breathing as a relevant source of mechanical stress-released active TGF-β1 ([@B87]). Nevertheless, the role of non-fibrotic but rather collapse-induced parenchymal stiffening in the context of extracellular (EC) TGF-β1 release to date has not been clarified. Finally, TGF-β1 overexpressing mice have been shown to develop surfactant dysfunction and high surface tension ([@B120]) including down-regulation of SP-C expression, by interfering with its transcription factor activity. In this context, considering the afore mentioned section, it becomes clear that an EC TGF-β1 pool bears the potential of an additional devastating loop by further compromising lung mechanics, potentiating epithelial injury.

Inflammatory Response Under Impaired Lung Mechanics -- Where Sterols Come Into Play {#S3.SS4}
-----------------------------------------------------------------------------------

The role of inflammation and inflammatory cells in fibrogenesis has been controversial over the last decades. Although anti-inflammatory medications have produced devastating clinical results in a IPF clinical trials ([@B167]; [@B89]), the role of immune cells, like AMs, in lung fibrogenesis and pulmonary tissue repair has been repetitively underscored ([@B223]; [@B224]; [@B175]; [@B91]; [@B187]; [@B165]). A promising link between mechanical stretch and inflammatory response may be the release of adenosine triphosphate (ATP) ([@B43]; [@B81]). Physiologically, mechanical stretch of AEC1 transmits the release of ATP via P2XR7, functioning as a stretch sensor ([@B158]; [@B137]). However, under prolonged alveolar injury concentrations of ATP and its related nucleotides sharply rise, finally overwhelming the degradative enzymatic machinery. Hence, levels of ATP continuously stay high in the early exudative stage of ARDS until the expression of its degrading ecto-enzyme catches up ([@B81]). Under these circumstances, ATP and its metabolites act as damage associated molecular patterns (DAMPs). This results in pro-inflammatory signaling on the one hand, but interestingly also in the induction of various profibrotic pathways on the other hand. In fact, high levels of EC ATP enhanced TGF-β1 expression and deposition of collagen 1 and fibronectin in fibroblasts via P2XR7 signaling *in vitro* ([@B217]; [@B166]). Meanwhile, ATP signaling via the same receptor enhanced the release of profibrotic tissue-metalloprotease inhibitor 1 (TIMP1), which attenuates the function of ECM-degrading enzymes, resulting in increased interstitial amounts of ECM, a hallmark of lung fibrosis ([@B75]). Interestingly, elevated levels of TIMP1 have also been observed in bronchoalveolar lavage fluid (BALF) of IPF patients, whereas expression of Timp1 was induced in 10 weeks old SP-C deficient mice ([@B21]). In addition, both Ca^2+^ and ATP are well-known stimulating agents of surfactant secretion ([@B214]; [@B49]; [@B158]; [@B50]). This may reflect a counteracting response, where surfactant secretion may be enhanced during high release of ATP and Ca^2+^, during injury.

Alternatively activated alveolar macrophages (aaAMs) are mainly characterized by expression of resistin-like alpha (Relm-α), chitinase-like proteins (YM1), inducible nitric oxide synthase (NOS-2) or arginase 1 (Arg-1) ([@B223]). Their profibrotic potential derives primarily through expression of TGF-β1 and the activation of latent TGF-β1 via matrix-metalloproteases (e.g., MMP-9) ([@B225]; [@B182]; [@B34]; [@B96]; [@B116]). Moreover, aaAMs haven been shown in topographic proximity to myofibroblasts, being highly capable of collagen secretion ([@B170]; [@B113]; [@B199]). Finally, aaAMs prime the alveolar micromilieu toward fibrosis by secreting various pro-fibrotic cytokines including IL-4, IL-10, IL-13 and the rather pro-inflammatory cytokine IL-1β. Of note, induced expression of YM1, a chitinase-like protein 1 ([@B14]; [@B196]; [@B223]), but also in SP-C deficient mice ([@B66]). Increased accumulation of macrophages with induced TGF-β1 expression was seen in bleomycin-challenged SP-C deficient mice in areas with significant parenchymal distortion. This further emphasizes the link between mechanical stress and macrophage regulation ([@B111]). Interestingly, this misbalance between classical and alternative differentiation was not solely dependent on SP-C deficiency, but also specific to the genetic 129/Sv6 background. The 129/Sv6 strain is characterized by an increased dietary cholesterol accumulation and has been described to develop foamy, lipid-laden macrophages with highly induced YM1 expression with age ([@B94]; [@B88]). Curiously, SP-C deficient mice as well as patients suffering mutant SP-C derived interstitial lung diseases (ILDs) related to mutations of SP-C, showed similar foamy macrophages in BALF and tissue as well as abundant cholesterol clefts ([@B66]; [@B80]; [@B1]; [@B178]). Taken together, this suggests a SP-C deficiency and cholesterol induced axis resulting in dysregulated macrophage metabolism and in misbalanced alternative differentiation ([Figure 3](#F3){ref-type="fig"}). Cholesterol clefts are present in aging 129/Sv4 mice ([@B88]), SP-C deficient mice ([@B66]; [@B178]) or aaAMs in human herpes virus (HHV)-induced lung fibrosis ([@B139]). Hence, this may be a potential morphological biomarker of dysregulated alternative activation and an indicator for lung fibrosis. However, the exact interplay between cholesterol and SP-C and macrophage regulation has not been yet elucidated. Nevertheless, studies from our group, suggested SP-C to be necessary for maintaining cholesterol homeostasis in an AM cell line (MHS cells) ([@B178]). In line with this, Romero and colleagues recently proposed the profibrotic potential of a lipid related paracrine axis between macrophages and epithelial cells ([@B175]). Interestingly, their team demonstrated the presence of foamy, lipid-laden macrophages overexpressing YM1 and TGF-β1 in bleomycin induced lung injury, which has been already associated with reduced expression of the *Sftpc* and *Sftpb* gene ([@B183]; [@B123]). Romero's team further showed oxidized phospholipids to be another crucial inductor of foam cell formation and alternative differentiation. The role of oxidized lipid species to induce foam cell formation in macrophages has been extensively studied in the field of atherosclerosis ([@B55]). Circulatory macrophages located in atherosclerotic plaques are frequently challenged with oxidized low-density lipoprotein (LDL), oxysterols or cholesterol. These lipids are endocytosed via various receptors, including CD36 and scavenger receptors. Accumulation of toxic lipid species decompensates the metabolic capacity of those macrophages, leading to cholesterol cleft formation and induction of necrotic factor kappa beta (NFκB) related cellular stress pathways. One central element in the so called "metaflammatory" process. This is the formation of the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, resulting in the production of pro-inflammatory cytokines including IL-1β and IL-18 ([@B53]; [@B169]). Importantly, macrophage derived IL-1β and inflammasome activation have been referred to as key features in various forms of lung fibrosis including IPF ([@B228]; [@B101]; [@B62]; [@B223]; [@B54]).

![Schematic role of SP-C in pulmonary metaflammation. **(Left panel**) comparison between the status of AE1C in the presence (healthy alveolus, top panel) or absence (damaged alveolus, bottom panel) of SP-C. **(Right panel**: **1) Priming signal:** TLR4 signaling is abrogated under the presence of mature SP-C. On the one hand, SP-C interferes with the complex formation of LBP and CD14 potentially attenuating TLR4 mediated NLPR3 priming in response DAMP/PAMP stimuli. This ant-inflammatory effect may be further potentiated by the N-terminal segment of SP-C transferring TLR4 activators either into neighboring phospholipid microsomes or directly to the cytoplasmic compartment of the macrophage ([@B38]; [@B61]). Moreover, maintained surfactant homoeostasis/surfactant catabolism counteracts the accumulation/formation of oxidized lipid species and cholesterol clefts on the one hand, and minimizes atelec- and volutrauma on the other hand ([@B178]), likely diminishing the release of DAMPS like ATP on the other hand. Together this prevents the buildup of inflammasome oligomerizing stimuli, what may at least partly explain the aberrant inflammatory response of SP-C KO mice to various inflammatory stimuli in contrast to WT mice ([@B70], [@B67]). **(Right panel: 2) Activating signal:** NLRP3 inflammasome comprises an initial NFκβ related priming phase, preceding a secondary activation signal ([@B194]): In the first step various proinflammatory DAMPS (oxysterols, oxidized PL species) or PAMPS (LPS) activate macrophages via TLR-4 signaling via an either LPS binding protein (LBP)/CD14 dependent or independent way ([@B38]; [@B61]). Thereby, LBP facilitates the binding of e.g., LPS to CD14, what accelerates LPS related TLR4 signaling. TLR4 signaling in turn drives NFκB-mediated expression of NLRP3, pro-IL-β1 and proIL-18 (Priming phase) ([@B62]; [@B194]). In the second step, multiple potential hits including PAMPS like extracellular ATP ([@B131]; [@B194]), intracellular cholesterol clefts ([@B55]), oxysterols and oxidized phospholipid derived mitochondrial oxidative stress ([@B57]; [@B129]) induce previously synthetized NLRP3 to form oligomers with caspase 1 and ASC leading to mature inflammasome formation. Thereby, increased level of extracellular ATP may be derived from mechanically stressed AEC1 ([@B81]), leading to an inflammasome activating K^+^ efflux via P2X7R. Meanwhile, SP-C deficiency related dysfunctional surfactant catabolism and surfactant dysfunction may favor the generation of oxidized PL species and the formation of cholesterol clefts ([@B58]; [@B178]). Likewise, these cholesterol crystals cause lysosomal stress, which in turn resembles another potent driving factor of inflammasome formation via induction of a K^+^ efflux. Finally, the active NLRP3 inflammasome converts inactive proIL-1β and proIL-18 into their active form IL-1β and IL-18. IL-1β promotes fibrotic remodeling ([@B62]; [@B35]; [@B222]; [@B124]). Meanwhile, another effect of accumulation of injurious lipid species inside the macrophages may also prime their hosts toward a profibrotic aaAM-phenotype ([@B175]) via induction of several aaAM related genes including, chitinase-like-3 (YM1), which has also been described to form electron dense crystals in various alternative activation of macrophages-disease models ([@B88]; [@B139]), what may result in a profibrotic feed-forward loop ([@B187]).](fphys-11-00386-g003){#F3}

In addition, cholesterol-induced "metaflammation" in macrophages may also be not only important in development of atherosclerosis but seems to be also highly relevant in the lung. For example, AMs are central elements in surfactant catabolism (comprehensively reviewed in [@B121]), and are continuously challenged with various phospho- and neutral lipids. Therefore, knocking down cholesterol transporters, such as ATP binding cassette transporter A1 (ABCA1) and G1 (ABCG1) leads to impaired cellular cholesterol efflux and cholesterol accumulation. In addition, those animal models showed respiratory distress, impaired surfactant metabolism and cholesterol cleft containing, lipid-laden AMs ([@B198]; [@B12]; [@B39]; [@B57]). Moreover, impaired reverse cholesterol transport in apolipoprotein E (ApoE) and apolipoprotein A1 (ApoA1) deficient mice was also linked to increased pulmonary oxidative stress and inflammation (in ApoE KO mice) as well as to foam cell formation and lung fibrogenesis (in ApoA1 KO mice) ([@B227]). Interestingly, surfactant function as well as metabolic integrity of AM was restored after application of cyclodextrin, a cholesterol sequestering-drug, underlining the injurious potential of cholesterol for surfactant function and pulmonary lipid homeostasis ([@B78]). The finding of cholesterol clefts and lipid laden macrophages in patients with SP-C mutations suggests impaired cholesterol homeostasis to be of relevance for development of lung disease in these patients ([@B80]; [@B1]; [@B134]; [@B45]; [@B118]).

Cholesterol overloaded macrophages exhibited an increased Toll-like receptor 4 (TLR-4) signaling mediated immune response as well as elevated expression levels of IL-1β, emphasizing a potential role of NLRP3 inflammasome activation in pulmonary macrophages ([@B57]). The NLRP3-inflammasome consists of three elements including the NLRP3, procaspase 1 and the apoptosis speck-like protein (ASC) containing a caspase recruitment domain (CARD), which links NLRP3 with procaspase 1 ([@B172]). In order to generate full activation of the inflammasome complex usually two independent signals are needed ([Figure 3](#F3){ref-type="fig"}): (1) a NFκβ priming signal TLR-4 signaling \[enhanced by lipopolysaccharide (LPS) or oxidized phospholipid species\] or the presence of cholesterol crystals ([@B19]; [@B55]; [@B58]; [@B143]; [@B180]) and; (2) purinergic signaling as may result from mechanical stress induced AEC1 injury ([@B81]). Elevated levels of ATP have been found in BALF of patients with lung fibrosis, further supporting the idea of EC ATP as a potential inflammasome co-activator ([@B171]). Hence, the NLRP3 inflammasome may resemble a crucial link between impaired lung mechanics and aberrant lipid metabolism in fibrosing lung diseases. Interestingly, IPF patients have been described to have elevated levels of unsaturated PC, a PC variant which highly susceptible for oxidative stress ([@B58]). In combination with the fact, that IPF occurs predominantly in the elderly and has been interlinked with cigarette smoking, mitochondrial stress and cellular senescence, factors driving the generation of reactive oxygen species (ROS). Thus, the IPF lung appears as a hotspot for lipid oxidation ([@B112]). Elevated levels of ROS and increased levels of cholesterol in surfactant are also present in bleomycin-induced lung fibrosis ([@B3]), highlighting the relevance of ROS, surfactant oxidation and foam cell formation in fibrogenesis. This is further supported by the presence foamy, Oil-Red-O positive cells in BALF of patients not only with *Sftpc* mutations, but also in patients with sporadic interstitial fibrosis ([@B16]).

Nevertheless, SP-C deficiency may play a distinct role in foam cell formation. Not only is SP-C crucial for stabilizing cholesterol-containing surfactant films ([@B72], [@B73]) and maintaining physiologic mechanical lung properties but also it seems to interfere with TLR-4 signaling. *In vitro* studies demonstrated that SP-C attenuates LPS induced cytokine production via TLR-4 signaling in a macrophage cell line, suggesting SP-C to play a role in innate immunity ([@B7]). Thereby, SP-C seems to compromise the affinity of TLR-4 to LPS via a complex interplay with CD14 ([@B38]). However, [@B61] also proposed a CD14 independent mechanism, by which the transfer of LPS into liposomes mediated by the N-terminal SP-C segment would prevent LPS binding to TLR4. This results in a reduced cytokine production upon LPS stimulation ([@B61]). In line with these findings, SP-C KO mice exhibited an increased inflammatory response upon LPS challenge characterized by increased macrophage accumulation and higher expression levels of IL-1β, IL-6 and tumor necrosis factor alpha (TNF-α) ([@B67]). Interestingly, SP-C containing phospholipid vesicles reduced TLR-4 signaling in these mice. Noteworthy, this immunomodulatory role of SP-C seems to not to be restricted to LPS and bacteria-induced inflammation, as SP-C also demonstrated an anti-inflammatory role under pathogen-free conditions ([@B55]). Taken all together, this suggest that SP-C may not only orchestrate the activation of TLR-4 in an infectious setting, but it also has an impact on TLR-4 signaling in macrophages induced by oxidized surfactant lipids, a question that, to date, remains unclear.

Assuming this hypothesis ([Figure 3](#F3){ref-type="fig"}), SP-C deficiency could predispose to TLR-4 activation by various oxidized cholesterol and PL species as well as their uptake. This results in proinflammatory signaling and NLRP3 inflammasome activation in macrophages ([@B210], [@B209]; [@B208]; [@B128]). Impaired lung mechanics induced by SP-C deficiency may further promote inflammasome activation by ATP release and at the same time, lead to accelerated surfactant aggregate conversion ([@B58]). Reduced amounts of surface-tension lowering large aggregates (LA) of surfactant, resulting from pronounced aggregate conversion to inactive small aggregates (SA), were accompanied by larger amounts of ROS susceptible phospholipid species ([@B66]; [@B80]; [@B109]; [@B193]; [@B83]; [@B117]; [@B181]). Increased uptake of SA by AMs in combination with SP-C disrupted cholesterol metabolism, which may partly explain the presence of foamy macrophages in the SP-C deficient lung and lung diseases related to SP-C mutated forms ([@B35]).

The relevance of inflammasome activation and IL-1β signaling in fibrotic parenchyma remodeling has been shown for silica induced- ILDs ([@B212]; [@B222]; [@B124]), bleomycin-induced lung fibrosis ([@B229]) and various other organ systems ([@B191]; [@B55]). NLRP3 associated IL-1β release mediates NFκβ activation via IL-1R1/myeloid differentiation primary response 88 (MyD88) related signal transduction in fibroblasts. This results in a misbalance between TIMP-1 and matrix-metalloprotease 9 (MMP-9) and 13 (MMP-13) promoting interstitial collagen deposition and fibrosis ([@B62]; [@B172]). Furthermore, genetic deletion of NLRP3-inflammasome associated genes in a ventilated-induced fibrosis model resulted in decreased rates of stretch-induced EMT, which was accompanied by ameliorated fibrotic lung remodeling ([@B124]).

SP-C, Cholesterol and Lung Mechanics. Evidences From Animal Models and Human Patients {#S4}
=====================================================================================

All the molecular and cellular mechanisms explained in the previous sections impact the health and mechanical properties of the lungs. We described in this section the results of deleting the expression or mutating SP-C in animal models ([Table 1](#T1){ref-type="table"}). In addition, we present here evidences from ILD patients, described to have different mutations in SP-C ([Table 2](#T2){ref-type="table"}).

###### 

SP-C related mouse models.

  Mouse model                                     General results                                                                                                                                           Lung morphology                                                                                                                                                                                                   BALF                                                                                                                                                                                                                                                                                                                         Lung mechanics                                                                                                                                                                                                                                    
  ----------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  **SP-C null mutants**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  [@B70]                                          Generation of SP-C null mutant mice, Swiss black background                                                                                               Viable, normal growth and reproducibility Reduced stability of small bubbles but normal activity at standard bubble size                                                                                          Indistinguishable from controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Reduced hysteresitivity at each end-expiratory pressure
  [@B69]                                          SP-C null mutant mice, 129/Sv background                                                                                                                  Reduced health and fecundity                                                                                                                                                                                      From 2 months: enlargement of alveoli, irregular alveolar septation, multifocal cellular infiltrates. From 6 month: type 2 cell hyperplasia, interstitial thickening, peribronchiolar and perivascular monocytic infiltration Intracellular lipid inclusions in macrophages and AE2C, cystoplasmic crystals in macrophages   Increased macrophage number                                                                                                                                                                                                                       Increased lung volumes at higher pressures, increased hysteresivity, increased airway resistance and tissue damping
  **2nd hit models**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  [@B68]                                          Intratracheal bleomycin application, Swiss black background                                                                                               Higher mortality and weight loss, more pronounced fibrosis and delayed resolution                                                                                                                                 Increased number of inflammatory cells, fibrotic foci (collagen, fibroblasts, destroyed septa), enhanced collagen deposition; delayed resolution of fibrosis                                                                                                                                                                 Increased neutrophil counts                                                                                                                                                                                                                       
  [@B67]                                          Bleomycin and rapamycin, S129S6 background                                                                                                                Preventive and therapeutic treatment with rapamycin failed to reduce bleomycin induced tissue inflammation and collagen deposition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  [@B28]                                          Instillation of Pseudomonas aeruginosa, 129S6 and FVB/N strain                                                                                            reduced survival of 2-week-old mice, increased bacterial colony counts in 2-week-old 129S6 but not in FVB/N mice                                                                                                  Increased inflammation, tissue and airway infiltrates (neutrophils and enlarged macrophages with cytoplasmic inclusions)                                                                                                                                                                                                     Increased total cell counts: neutrophils; large foamy macrophages                                                                                                                                                                                 
  [@B110]                                         Respiratory syncytial virus infection, 129S6 and FVB/N                                                                                                    Higher susceptibility to RSV and delayed resolution of induced changes in lung morphology in both strains                                                                                                         More extensive interstitial thickening, air space consolidation, goblet cell hyperplasia.                                                                                                                                                                                                                                    Increased total cell counts: polymorphonuclear leucocytes, lymphocytes, enlarged foamy mononuclear cells                                                                                                                                          
  [@B147]                                         RSV infection, expression of SP-C inducible by doxycycline (on 129S6; *55.3/Sftpc-/-*)                                                                    SP-C expression reduced RSV-induced tissue inflammation and inflammatory cell counts and increased viral clearance                                                                                                Diffuse alveolar and interstitial infiltrates in doxycycline untreated mice, reduced inflammation in doxycycline treated mice                                                                                                                                                                                                Reduced total cell counts and percentage of neutrophil counts in doxycycline -treated mice                                                                                                                                                        
  [@B211]                                         LPS challenge, 129S6 background                                                                                                                           More intense airway and airspace inflammation, delayed resolution of tissue inflammation                                                                                                                          More intense cellular infiltration, perivascular edema, fragmentation of alveolar septa; residual inflammation 30 days post LPS exposure                                                                                                                                                                                     Increased total cell counts without LPS challenge (reduced by application of Survanta)                                                                                                                                                            
  **Models with incomplete proSP-C processing**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  [@B97]                                          Deletion of exon 4                                                                                                                                        Not viable                                                                                                                                                                                                        Fetal lung tissue: disrupted lung organogenesis, branching morphogenesis, dose-dependent cell cytotoxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  [@B91]                                          Conditional expression of L188Q upon doxycycline; intratracheal bleomycin                                                                                 No spontaneous pulmonary fibrosis; more extensive fibrosis in response to bleomycin                                                                                                                               Increased apoptosis, total lung collagen, higher number of myofibroblasts after bleomycin                                                                                                                                                                                                                                    Cell numbers unaltered in bleomycin treated WT and mutant mice                                                                                                                                                                                    More reduced static lung compliance in bleomycin treated L188Q mice than challenged controls
  [@B44]                                          Conditional mouse mutant, constitutive and inducible I73T expression (by Tamoxifen), C57BL/6J                                                             Increased early mortality, spontaneous acute alveolitis, parenchymal injury, fibrotic remodeling                                                                                                                  Constitutive I73T expression: diffuse parenchymal lung remodeling; disrupted embryonic lung architecture Induced expression: acute, diffuse lung injury after tamoxifen, partial recovery but development of fibrotic phenotype                                                                                              Constitutive expression: age-dependent increases in BALF cellularity induced expression: increased total cell counts, early macrophage accumulation, followed by polymorphonuclear cells and eosinophilia, milder increase in total lymphocytes   Induced expression: restrictive pattern (PV loops), decreased static compliance
  [@B44]                                          Conditional mouse mutant, I73T expression induced by Tamoxifen; Local and i.v application of clodronate                                                   Multiphasic and multicellular alveolitis; local clodronate application reduced survival, i.v. clodronate improved survival and reduced eosinophilia                                                                                                                                                                                                                                                                                                                                                                                            Early reduction of macrophages, followed by accumulation of immature macrophages, neutrophils and eosinophils                                                                                                                                     
  [@B44]                                          Constitutive and conditional C121G mutant inducible by tamoxifen, C57BL/6J                                                                                Constitutive expression: lethal postnatal respiratory failure Conditional expression in adult mice: dose-dependent morbidity and mortality, multiphasic polycellular alveolitis with increased BALF cell counts   Constitutive: distorted architecture, enlarged airspaces, interstitial widening, inflammatory infiltrates, proteinaceous fluid conditional expression: acute diffuse lung injury, partial recovery but spontaneous fibrotic lung remodeling                                                                                  Conditional expression: polycellular alveolitis, increased total cell counts, early macrophage increase, followed by neutrophils and eosinophils, milder increase in lymphocytes                                                                  Restrictive pattern: decline in static lung compliance
  [@B44]                                          Sterile injury model (surfactant protein C-thymidine kinase) induced by ganciclovir in presence (SPC-TK) and absence (SPC-TK/SPC-KO) of SP-C expression   Increased injury and higher mortality in absence than in presence of SP-C expression                                                                                                                              Diffuse alveolar damage qualitatively similar but more pronounced in SPC-TK/SPC-KO                                                                                                                                                                                                                                           Total cell counts unaltered in SPC-TK/SPC-KO and SPC-TK, higher neutrophils and lymphocyte cell counts in SPC-TK/SPC-KO                                                                                                                           
  [@B200]                                         Expression of SP-C~24--57~ HA, FVB/N                                                                                                                      Delayed/arrested lung development and lethal neonatal respiratory distress syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

###### 

Lung mechanics and BALF cells data from patients.

  Variant                                                                                  BALF cells                                                                                                   Lung mechanics                                                                                                                                                                                                                                                                   References
  ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  L188Q                                                                                                                                                                                                 TLC 52%, DLCo 51% (male patient, onset 20 years); FVC21% (female patient, onset 17 years)                                                                                                                                                                                        [@B46]
  I73T                                                                                     85% M, 12% L, 3% N                                                                                                                                                                                                                                                                                                                                                                            [@B151]
  R167Q                                                                                    84% M, 11% L, 5% N                                                                                                                                                                                                                                                                                                                                                                            
  I73T                                                                                     92% M, 7% N, 1% L, 0% E                                                                                      FRC: 69% (8m), 77% (13 years) DLCo: 25% (8m), 51% (13y)                                                                                                                                                                                                                          [@B108]
  I73T                                                                                     30% M, 60% N, 10% L, 0% E (Moraxella catarrhalis)                                                            FRC: 138% (36m), DLCo: 111% (33m), 128% (36m), 156% (42m)                                                                                                                                                                                                                        
  I73T                                                                                     82% M, 13% N, 3% L, 2% E                                                                                     FRC: 120 (26m), 128 (35m), 73% (39m) DLCo: 98% (26m), 89% (35m), 164% (39m)                                                                                                                                                                                                      
  I73T                                                                                     84% M, 5% N, 11% L, 0% E                                                                                                                                                                                                                                                                                                                                                                      
  I73T                                                                                     93% M, 1% N, 6% L, 0% E                                                                                      FRC 112% (26m), DLCo: 87% (26m)                                                                                                                                                                                                                                                  
  15x I73T, 1x V39A, c.325- 1G \> A, c.424delC, c.435G \> C (Q145H), L188P, C189Y, L194P   70 ± 5M, 8 ± 2L, 18 ± 4% N, total: 379 ± 56 × 10^3^                                                          82% patients with SpO~2~ testing \< 95%                                                                                                                                                                                                                                          [@B9]
  I73T                                                                                     40% M, 57% N, 3% L (mother 32 years)                                                                         FVC 62%, TLC 77%, FEV1: 83%, RV: 108%, DLCo: 33%, PaO~2~ room air 11.3 kPa, PaO~2~ after 10 min exercise(35W): 7.3 kPa                                                                                                                                                           [@B205]
                                                                                           74% M, 20% N, 4% L, 2% E (child, 3 months)                                                                                                                                                                                                                                                                                                                                                    
  G100S                                                                                    BAL cell count (100.000 cells/ml): 2.4, 90% M, 7.5% L, 2.5% N, 0% E, CD4/CD8 ratio: 1,7                      VC%: 72.2, FEV1: 84.1% DLCo: 69.3%                                                                                                                                                                                                                                               [@B85]
                                                                                           BAL cell count (100.000 cells/ml): 2, 86% M, 12% L, 1% N, 1% E, CD4/CD8 ratio: 1.6                           VC%: 85, FEV1: 90.3% DLCo: not available                                                                                                                                                                                                                                         
                                                                                           BAL cell count (100.000 cells/ml): 1.4, 91% M, 5.8% L, 2.4%N, 0.8% E; CD4/CD8 ratio: 1.5                     VC%: 96.6, FEV1: 85% DLCo: 65.2%                                                                                                                                                                                                                                                 
                                                                                           BAL cell count(100.000 cells/ml): 1.21,: 54.2% M, 10.1% L,34.5% N, 1.2% E, CD4/CD8 ratio: 0.25               VC%: 42.5, FEV1: 92.9% DLCo: 38.5%                                                                                                                                                                                                                                               
                                                                                           BAL cell count (100.000 cells/ml): 3.85, 80% M, 17.3%L, 1.1%N, 1.6% E, CD4/CD8 ratio: 0.6 (time diagnosis)   VC%: 65.3, FEV1: 83.3% DLCo: not available (at time diagnosis)                                                                                                                                                                                                                   
  Y104H                                                                                    91% M, 8% L, 1% N                                                                                            FVC:85%, DLCo: 89%, oxygen saturation 97% to 95% (with exercise)                                                                                                                                                                                                                 [@B181]
  I73T                                                                                                                                                                                                  16 years: 90% FVC, 86% TLC, 96% DLCo, 96% VO~2~ max; 37 years: FVC 65%, TLC 91%, DLCo 42%, VO~2~max: 54%                                                                                                                                                                         [@B40]
  I38F                                                                                                                                                                                                  14 years: FVC 77%, TLC 90%, DLCo 108%, VO~2~ max 78%; 32 years: FVC 94%, TLC 96%, DLCo 82%, VO~2~max 69%, high breathing reserve: 115l/min, saturation 100% at peak exercise                                                                                                     
  I73T                                                                                                                                                                                                  7 years: FVC 59%, TLC 95% DLCo not available, VO~2~max 80%, 28 years: FVC 46%, TLC 48%, DLCo 58%, VO~2~max 79%                                                                                                                                                                   
  I73T                                                                                                                                                                                                  8 years: FVC 69%, TLC 100%, DLCo 107%, VO~2~ max 83%, 29 years: FVC 102%, TLC 106%, DLCo 95%, VO~2~max 83%                                                                                                                                                                       
  V39L                                                                                                                                                                                                  16 years: FVC 88%, TLC 95%, DLCo 109%, VO~2~max 93%; 37 years: 94% FVC, 96% TLC, 82% DLCo, 91% VO~2~max                                                                                                                                                                          
  C121F                                                                                    Infiltration of granulocytes and alveolar macrophages                                                                                                                                                                                                                                                                                                                                         [@B193]
  I73T                                                                                                                                                                                                  4 months: 88% oxygen saturation, respiratory rate 85, V~T~ 6.0 ml/kg, V~E~ 507 ml/min/kg, Crs 2.96 ml/cmH2O, Crs/kg 0.76/kg, VC 92 ml(52%), TLC 196 ml(74%), FRC 128 ml(110%), RV 104 ml(99%), V~max~FRC 416 ml/s (263%), FEF~75~ 410 ml/s (207%), FEF~85~ 295 ml/s (258%)       [@B65]
  I38F                                                                                                                                                                                                  3.3 months: oxygen saturation: 91%, respiratory rate 77, V~T~ 6.3 ml/kg, V~E~ 484 ml/min/kg, Crs 2.26 ml/cmH2O, Crs/kg 0.59/kg, VC 28 ml(69%), TLC 211 ml(94%), FRC 138 ml(125%), RV 108 ml(109%), V~max~FRC 343 ml/s (245%), FEF~75~ 579 ml/s (334%), FEF~85~ 477 ml/s (476%)   
  I73T                                                                                     Normal cytology and lipid index                                                                                                                                                                                                                                                                                                                                                               [@B66]
                                                                                           Lipid-laden alveolar macrophages                                                                                                                                                                                                                                                                                                                                                              
  Glutamine instead leucin at 188                                                                                                                                                                       Normal lung volumes, diffusion capacity 18% of predicted                                                                                                                                                                                                                         [@B111]
  E66K                                                                                     Increased cellularity with foamy mononuclear cell                                                                                                                                                                                                                                                                                                                                             ([@B111])

Summary of data from patients suffering fibrosis related to a SP-C mutation. Changes in BALF cells and lung mechanics are summarized for the available data. Crs, respiratory system compliance; PaO

2

, partial pressure of oxygen; RV, residual volume; VC, vital capacity; V

E

, minute ventilation; V

T

, tidal volume; VO

2

max, maximal oxygen uptake; FEF

75

, Forced expiratory flow at 75% of forced vital capacity; FEF

85

, Forced expiratory flow at 85% of forced vital capacity. M, macrophage; N, neutrophil; L, lymphocyte; E, eosinophil.

SP-C Modifications in Animal Models {#S4.SS1}
-----------------------------------

[@B65], [@B66] reported the generation of SP-C null mutant mice deficient in the expression of *Sftpc* in a Swiss black background. SP-C deficient mice were viable at birth and did grow and reproduce normally with only mild alterations in lung mechanics. In addition, *in vitro* studies of the SP-C deficient derived surfactant proved reduced stability of small bubbles but normal activity at normal bubble size using a captive bubble surfactometer ([@B65], [@B66]). In contrast, in 129/Sv background, SP-C deficient mice presented with severe morphological changes including enlargement of alveoli, AE2C hyperplasia and interstitial thickening together with a peribronchiolar and perivascular monocyte infiltration in some animals. Although areas of thickened alveolar septa stained positive for alpha-smooth muscle actin and blue in trichrome staining, septa were thinner in regions of airspace enlargement and total lung hydroxyproline remained unaffected ([@B111]; [@B70], [@B67],[@B68]; [@B69]; [@B178]). Importantly, lung structure was normal at birth, but emphysema and remodeling developed upon aging suggesting a process of ongoing injury and repair. Investigation of pulmonary mechanics exhibited increased lung volumes at higher pressures as well as increased hysteresivity in SP-C deficient mice. Abnormal intracellular lipid inclusions and crystals were observed in macrophages and AE2C ([@B65], [@B66]). While phospholipid content was normal in SP-C deficient lungs on the swiss black background, it was 2-fold elevated in 129/Sv background. In addition, lung mechanics showed increased lung volume at high pressure, tissue damping and hysteresivity in 129Sv background. Together, both studies show strain specific influences on the severity of the pulmonary phenotype ([@B94]). Interestingly, as mentioned before, the 129Sv strain demonstrates an increased absorption of dietary cholesterol ([@B111]; [@B70], [@B67],[@B68]; [@B69]) which might also contribute to the strain specific phenotype in *Sftpc* null mice.

Further investigations included additional hits aggravating the effects of SP-C deficiency ([@B111]). Intratracheal application of bleomycin led to higher mortality, more pronounced weight loss, increased neutrophil counts and enhanced collagen deposition in SP-C deficient mice compared to controls. Increased fibrosis as additionally indicated by morphological parameters went along with a delayed resolution of bleomycin-induced fibrosis ([@B125]). Preventive and therapeutic treatment with rapamycin failed to reduce bleomycin induced tissue inflammation and collagen deposition in SP-C deficiency ([@B70]). Instillation of *Pseudomonas aeruginosa* increased pulmonary injury and bacterial colony counts in SP-C deficient mice compared to control mice. As for unchallenged SP-C deficient mice, sensitivity to *Pseudomonas* challenge seemed to be strain specific since bacterial cell counts were enhanced in 129/Sv6 strain but unaltered in age-matched FVB/N mice. Further, neutrophils and enlarged macrophages with cytoplasmic inclusions were observed upon *Pseudomonas aeruginosa* challenge in absence of SP-C whereby the phagocytic index of macrophages in the SP-C deficient mouse model was reduced ([@B71]). Similarly, SP-C deficient mice were more susceptible to respiratory syncytial virus (RSV) infection and resolution of RSV-induced alterations in lung morphology was delayed. Mice exhibited more extensive interstitial thickening, air space consolidation and goblet cell hyperplasia. Polymorphonuclear and macrophage cell counts were increased in BALF obtained from SP-C deficient mice as well as viral titers in lung homogenate ([@B70]; [@B69]). In contrast to challenge with *Pseudomonas aeruginosa*, increased susceptibility of SP-C deficient mice to RSV was not restricted to 129/Sv6 strain but also observed in FVB/N background ([@B68]). However, induction of SP-C expression in compound transgenic mice could reduce RSV-induced tissue inflammation and inflammatory cell counts ([@B68]). LPS-challenged mice develop more intense airway and airspace inflammation in the absence of SP-C. While control mice demonstrate a rapid resolution of LPS-induced cellular and tissue inflammation, inflammation persisted longer in SP-C deficient mice. Cell culture experiments further demonstrated increased LPS-induced cytokine expression of SP-C deficient AE2C compared to those from controls ([@B70]).

The model studied by [@B65], [@B28] represents a null mutant mouse model without sufficient *Sftpc* expression leading to the absence of SP-C and proSP-C. Other models include mutations that cause aberrant accumulation of SP-C precursor proteins. Deletion of exon 4 (g.1728 G3A), a mutation detected in human SFTPC, resulted in a truncated form of SP-C (SP-CΔexon4) and incomplete pro-protein processing. Affected mice exhibited disrupted lung organogenesis, branching morphogenesis and expression-depended epithelial cell cytotoxicity ([@B110]). Further, transgenic mice that express the mutant L188Q SP-C did not develop pulmonary fibrosis spontaneously, despite induction of ER stress, but developed a more extensive pulmonary fibrosis with reduced compliance and enhanced AEC apoptosis in response to bleomycin and authors suggested alveolar epithelial ER stress to play a crucial role in enhanced disease development ([@B147]). Recently, [@B147] developed a conditional mouse mutant in which the expression of I73T, the most common SFTPC mutation found in human patients, is regulated by tamoxifen. In their study, expression of the human mutation induced a spontaneous acute alveolitis, followed by parenchymal injury and fibrotic remodeling in mice ([@B147]). Tamoxifen controlled expression of isoleucin to threonine substitution at codon 73 in *Sftpc* (I73T) results in misprocessed proSP-C and leads to increased mortality at day 7 to 14 and acute diffuse parenchymal lung injury with polycellular alveolitis. An early influx of polymorphonuclear cells and macrophages was followed by eosinophilia. Partial recovery from acute injury was followed by aberrant remodeling, collagen deposition and AE2C cell hyperplasia and mechanical abnormalities. Pressure-volume curves displayed a restrictive pattern at 4 to 6 weeks post-tamoxifen and static compliance was reduced at week 4 but rose with resolution of inflammation. However, the fibrotic phenotype was preceded by TGF-β1 ([@B211]). A detailed analysis of the same model showed an early reduction of macrophages, followed by an accumulation of immature macrophages and neutrophils before onset of eosinophilia at week 2 in combination with shift from proinflammatory to anti-inflammatory/profibrotic activation state in mRNA BALF cell analysis ([@B211]). Total inspiratory capacity and static compliance were reduced in transgenic mice following the induction of the mutant protein whereas tissue damping was elevated, all together suggesting an enhanced tissue stiffness. While local clodronate application diminishing resident macrophages led to reduced survival, intravenous application of clodronate decreased accumulation of immature macrophages, improved survival and reduced eosinophilia ([@B97]). Expression of another mutant protein, C121G, resulted in postnatal respiratory failure due to disrupted lung morphogenesis with enlargement of airspaces and interstitial widening in mice constitutively expressing C121G whereas a tamoxifen-mediated expression in adult mice induced acute parenchymal lung injury and a multiphasic polycellular alveolitis with increased BALF cell counts. Similar to the I73T model, an early increase of macrophages and neutrophils was followed by a later influx of eosinophils. Overall, lung mechanics showed a restrictive impairment indicated by a decline in static lung compliance ([@B146]).

SP-C Mutations in Human Patients {#S4.SS2}
--------------------------------

Since [@B151], [@B118] described the first case of a *Sftpc* mutation in an infant girl and her mother diagnosed with ILD ([@B197]; [@B151]; [@B108]; [@B9]; [@B85]), several studies have been conducted to provide a link between variants in *SFTPC* and the manifestation of ILDs in adults or children. Since previous groups have already performed systematic reviews describing detected mutations, clinical parameters and radiographic as well as histological findings ([@B197]; [@B151]; [@B108]; [@B9]; [@B85]), we decided to focus on the work that reported either BALF cell counting or data on lung mechanics in their study ([Table 2](#T2){ref-type="table"}). In general, lung mechanics display a restrictive pattern ([@B197]; [@B151]; [@B108]; [@B9]; [@B85]). In particular, vital capacity, forced vital capacity were markedly reduced in some patients ([@B46]; [@B151]) whereas mild reductions in forced expiratory pressure in 1 s (FEV1) ([@B46]; [@B85]) were attributable to a generally reduced lung volume and not indicative of an obstruction. However, the reported residual volumes were high to normal ([@B197]; [@B1]; [@B46]; [@B151]; [@B9]). Changes in functional residual capacity (FRC) were unspecific. While some patients demonstrated a reduced FRC, other studies reported elevated or normal values. Gas exchange as indicated by diffusing capacity for carbon monoxide exhibited distinct impairment in most ([@B200]; [@B85]) resulting in a generally reduced oxygen ([@B1]). However, Abou Taam and coworkers reported normal and increased diffusion capacity for carbon monoxide (D~LCO~) in two patients ([@B9]) and oxygenation was sufficient in another patient reported by [@B109]. Hence, heterogeneity of the disease is also reflected in lung function. While the majority of studies linked SFTPC mutations to the familial form of pulmonary fibrosis, genetic mutations in SFTPC were also detected in a subset of patients suffering from sporadic IPF ([@B46]). Interestingly, sporadic patients also demonstrate with mixed pattern as reported by [@B146], [@B40], [@B80], [@B109], [@B33], [@B193], [@B192], [@B134], [@B200], [@B42], [@B155]. Indeed, they reported a case of combined pulmonary fibrosis and emphysema in a patient with the most common I73T mutation.

As explained before, pulmonary fibrosis and especially IPF was linked to an AE2C dysfunction and increased ER stress response due to aberrant protein accumulation. Hyperplastic AE2C in histological examination are a common finding ([@B104]) and enhanced ER stress is a widely acknowledged pathomechanism in IPF ([@B216]). However, reduced transcription of SFTPC due to promotor variant were associated with neonatal respiratory distress syndrome in late preterm infants ([@B5]) and SP-C was absent in BALF samples of a family with chronic ILDs, together with reduced pro-SP-C staining, though no mutation was identified ([@B40]; [@B80]; [@B203]; [@B176]; [@B193]; [@B31]; [@B76]; [@B134]; [@B46]; [@B42]; [@B83]; [@B84]; [@B204]; [@B2]; [@B9]; [@B205]; [@B107]; [@B117]; [@B159]; [@B74]; [@B119]; [@B82]). While the majority of mutations leads to the onset of ILDs already in childhood ([@B109]; [@B184]; [@B132]; [@B207]; [@B46]; [@B151]; [@B108]) a subset of variants results in a manifestation in later child- or adulthood ([@B80]; [@B1]; [@B134]; [@B46]; [@B118]) suggesting a chronic process.

Besides to AE2C hyperplasia, cholesterol clefts are frequently detected on lung biopsy in context of an SFTPC mutations ([@B5]) or on lung specimen from ILD patients lacking SP-C ([@B109]; [@B193]; [@B79]; [@B83]). Macrophages were often described as foamy ([@B117]; [@B181]) or lipid-laden ([@B203]; [@B1]; [@B200]; [@B151]). When analyzing BALF cells, the majority of cells usually consists of macrophages ([@B200]; [@B46]). However, some samples showed a marked increase in neutrophil ([@B203]; [@B151]) or lymphocyte ([@B178]) cell counting in the absence of an infection. Whether immune cell infiltration occurs in reaction to abnormal histological findings or rather causes alterations remains unclear in view of single time point studies in human patients. In addition, a detailed characterization of macrophages was not provided by the majority of studies, but different activation could have distinct effects on fibrogenesis.

Lung Fibrosis and Cholesterol {#S5}
=============================

Recently, we have described the accumulation of cholesterol crystals in AMs of SP-C deficient animals ([@B178]). We also showed similar crystals accumulated in the lung of an IPF patient. Looking through the literature this feature is commonly described ([@B66]; [@B88]; [@B139]) but no further investigated. Therefore, the role of cholesterol or accumulation of cholesterol in the form of crystals in cells is yet not well understood and often overlooked. As explained before, cholesterol is also involved in many processes apart from regulating membrane biophysical properties. Not many experimental data are available in the context of the influence of cholesterol in lung diseases. However, in the clinic settings, it is not surprising that certain patients are suffering from comorbidities that should be treated such as hypercholesterolemia. In fact, it is known that IPF increases the risk of heart diseases. Thus, it is common for IPF patients to receive medications aimed at reducing cardiovascular risk, including statins, which lower cholesterol levels ([@B226]). Data in this regard is still quite controversial. While, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) aggravated pulmonary fibrosis in mice by increased production of mitochondrial ROS and NLRP3 inflammasome activation in macrophages. Statins, as potent inhibitors of the endogenous cholesterol synthesis have been associated with a lower decline in FVC in a cohort of untreated IPF patients ([@B15]). In line with this, diet induced systemic hyperlipidemia resulted in altered surfactant phospholipid composition leading to increased alveolar collapsibility, providing evidence that pulmonary lipid homeostasis is strongly related to the blood circulation ([@B233]). As approximately 83% of surfactant cholesterol has been stated to be derived from blood plasma ([@B136]), statins could contribute in preventing deleterious high levels of cholesterol in surfactant films, providing surfactant film stability and avoiding alveolar collapse. In addition, evaluation of lung function showed that patients receiving statin therapy and Ofev had less decline in pulmonary capacity, compared with a placebo ([@B106]). The yardstick that researchers used was patients' annual rate of decline in forced vital capacity (FVC). The results suggested that statins do not diminish Ofev's effectiveness ([@B115]; [@B90]).

Statins may also have an anti-inflammatory effect in the lung ([@B197]), thus a multifactorial mechanism may play an important role in their use. In conclusion, more experimental evidence is needed to support the use of cholesterol lowering drugs for the treatment of lung diseases such as fibrosis. In addition, the role of cholesterol and SP-C has to be further described and understood in order to develop new therapies. However, there is already promising data in this regard, opening a new pathway to target.

Conclusion {#S6}
==========

Summing up there are various potential either direct or indirect mechanisms how SP-C is able to interfere and modulate fibrogenesis in the lung. While SP-C deficiency mediated surfactant dysfunction and impaired lung mechanics are likely contributors in the generation of local mechanical stresses and strains, its biophysical interplay with cholesterol on the one hand, and its modulation of TLR-4 signaling on the other hand, highlights SP-C as a key element in a complex profibrotic network. Thereby SP-C deficiency comes into play not only in animal models, but also in patients with familial and non-familial forms of lung fibrosis such as IPF. Further research is needed in order to determine the potential of cholesterol lowering drugs as treatment or combined with anti-fibrotic drugs to find a better therapy for IPF patients.
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:   alternatively activated alveolar macrophages
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:   ATP binding cassette transporter A1
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:   adenosine-deaminase

ADP
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AMP
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:   caspase recruitment domain
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EC
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:   extracellular matrix

EMT
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:   endoplasmic reticulum
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:   chloride acid
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HRCT

:   high resolution computed tomography
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:   idiopathic pulmonary fibrosis
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LAP-1

:   latency associated peptide 1

LDL

:   low-density lipoprotein

LPS

:   lipopolysaccharide
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:   latency TGF- β 1 binding protein-1

mRNA

:   messenger ribonucleic acid

MMP-9

:   matrix-metalloprotease 9

MMP-13

:   matrix-metalloprotease 13

MyD88

:   myeloid differentiation primary response 88

NF κβ

:   necrosis factor-kappa-beta

NLRP3 NOD-

:   LRR- and pyrin domain-containing protein 3

NOS-2

:   inducible nitric oxide synthase

NRDS

:   neonatal respiratory distress syndrome

PAP

:   pulmonary alveolar proteinosis
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:   phosphatydilcholine

PEEP

:   positive end-expiratory pressure

P2XR7

:   P2X purinoreceptor 7
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:   P2X purinoreceptor 4

P2Y2R

:   P2Y purinoreceptor 2

Relm-α

:   resistin-like alpha

ROS

:   reactive oxygen species

RSV

:   respiratory syncytial virus

SA

:   small aggregate

SHH

:   sonic hedgehog

SP-B

:   surfactant protein B

SP-C

:   surfactant protein C

SFTPC

:   surfactant protein C gene

TGF-b1

:   transforming growth factor beta 1

TIMP1

:   tissue-metalloprotease inhibitor 1

TLC

:   total lung capacity

TLR-4

:   Toll-like receptor 4

TNF- α

:   tumor necrosis factor alpha
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:   chitinase-like protein 1.
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